Noom Launches Noom Vibe, a Wellness Community and Habit Tracker Built for the Age of GLP-1s
03 juin 2024 08h04 HE
|
Noom Inc
Noom Launches Noom Vibe, a New Free Wellness Community App
Elevai Labs Inc Subsidiary, Elevai Biosciences, to Present at the UCLA LA-BEST 2024 Conference
22 mai 2024 16h15 HE
|
Elevai Labs Inc.
Elevai Labs Inc Subsidiary, Elevai Biosciences, to Present at the UCLA LA-BEST 2024 Conference
Elevai Biosciences Highlights Preclinical Data Showing Potential of In-Licensed Asset “EL-22” for The Treatment of Obesity
02 mai 2024 08h30 HE
|
Elevai Labs Inc.
Elevai Biosciences Highlights Preclinical Data Showing Potential of In-Licensed Asset “EL-22” for The Treatment of Obesity
Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments
01 mai 2024 09h00 HE
|
Elevai Labs Inc.
Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments
Rani Therapeutics Announces Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Triagonist
14 déc. 2023 08h00 HE
|
Rani Therapeutics, LLC
- Transenteric delivery of incretin triagonist of GLP-1, GIP, glucagon receptors elicits rapid weight loss in animal study – - Preclinical data support the potential for the RaniPill platform...
Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in Development
14 nov. 2023 07h30 HE
|
Entera Bio Ltd.
JERUSALEM, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”), a leader in the development of orally delivered peptides and small therapeutic proteins,...